A Phase 2 interventional study of Trastuzumab and Paclitaxel in Neoplasms, Breast, sponsored by GlaxoSmithKline. Completed at 23 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-11.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
How we know · 10 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 125th largest by enrollment of the 366 interventional ones that give a count, is one of 19 that started in 2007, is one of 239 in phase 2, and was the 104th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 19 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
59 studies in Breast Neoplasms by GlaxoSmithKline: 1 open now, 3 under way, 1 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Breast Neoplasms by GlaxoSmithKline, this one is the 19th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2007, is one of 26 in phase 2, and was the 28th registered.
GlaxoSmithKline’s Breast Neoplasms studies by the year they started, since 2002.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among GlaxoSmithKline’s 59 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will examine safety and efficacy of Lapatinib in combination with a standard neoadjuvant chemotherapy including 5FU, Epirubicin, Cyclophosphamide and Paclitaxel. Tumor tissue will be obtained at 3 timepoints (optional 4th) to evaluate tumor response to treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Table 1 Baseline Laboratory Values
Hematologic:
(absolute neutrophil count) >1.5 x 109/L >9 g/dL >75 x 109/L
Hepatic:
albumin >2.5 g/dL serum \<1.25 x / ALT \<3 x ULN if no documented liver AST / ALT \<3 x ULN with documented liver metastases
Renal:
serum creatinine \<2.0 mg/dL
Non- (i.e., women with functioning ovaries who have a current documented tubal ligation or hysterectomy, or women who are )
Child-bearing potential (i.e., women with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility.) This category includes women with oligomenorrhea (severe), women who are perimenopausal, and young women who have begun to menstruate. These subjects must have a negative serum pregnancy test at screening and agree to one of the following:
Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication; or Consistent and correct use of one of the following acceptable methods of : male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject; any intrauterine device (IUD) with a documented failure rate of less than 1% per year; oral contraceptives (either combined or progestogen only) where not for this subject population or per local practice.; or barrier methods, including diaphragm or condom with a spermicide.
Please note that breast cancer subjects on this trial cannot receive injectable levonorgestrel or injectable progestogen due to the potential for an adverse effect of anti-hormonal therapies on chemotherapy administered for breast cancer [Albain, 2002]. Progestogen may also affect the proliferative rate of endocrine-responsive tumors.
Exclusion Criteria:
History of uncontrolled or symptomatic angina History of arrhythmias requiring medications, or Myocardial infarction \<6 months from study entry Uncontrolled or symptomatic congestive heart failure below the institutional normal limit Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trastuzumab alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles and Paclitaxel for 4 (21 day) cycles then continued trastuzumab until time of definitive surgery
Drug: Trastuzumab · Drug: Paclitaxel · Drug: FEC75
Lapatinib alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued lapatinib until time of definitive surgery
Drug: Paclitaxel · Drug: FEC75 · Drug: Lapatinib
Trastuzumab + Lapatinib for 2 weeks then added FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued trastuzumab + lapatinib until time of definitive surgery
Drug: Trastuzumab · Drug: Paclitaxel · Drug: FEC75 · Drug: Lapatinib
4mg/kg IV loading dose followed by 2mg/kg IV weekly
80mg/m2 IV weekly for 4 (21 day) cycles
5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy
A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ \[DCIS\] or lobular carcinoma in situ \[LCIS\] was allowed). A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus). Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes. 26 weeks of therapy comprised the 2-week run-in phase, 12 weeks of treatment with FEC, and 12 weeks of treatment with Paclitaxel.
Time frame: Week 26
Percentage of Participants With Clinical Complete Response (cCR) at 26 Weeks or at End of Treatment (EOT) or Early Withdrawal
cCR was defined as the percentage of participants achieving either a Complete Response (CR) or a Partial Response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.
Time frame: Week 26 or EOT or Early withdrawal
Percentage of Participants (Par.) With Disease-free Survival (DFS) at the End of 5 Years From Randomization
Percentage is the Kaplan Meier estimate of DFS. DFS is time from randomization until disease recurrence (contralateral breast cancer; second primary cancer; progression during neo-adjuvant treatment; or death from any cause). Par. who experienced progression during treatment and were withdrawn were considered to have a DFS event at withdrawal.
Time frame: From first dose date until disease progression, assessed up to a maximum of 5 years
Number of Participants With the Indicated Electrocardiogram (ECG) Status at Baseline and at EOT or Early Withdrawal
12-lead ECGs were performed, and participants were classified as having normal ECG, abnormal- not clinically significant (NCS) ECG, and abnormal-clinically significant (CS) ECG per investigator opinion and reported result.
Time frame: Baseline and EOT (up to Week 26) or Early withdrawal
Cumulative Number of Participants With at Least One Decrease of More Than or Equal to 20% in Left Ventricular Ejection Fraction (LVEF) at the Indicated Time Points Compared to LVEF at Baseline
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction and is used to determine cardiac function. LVEF was measured by performing echocardiogram (ECHO). If ECHO could not be performed or if the investigator believed that it was not conclusive to evaluate LVEF, then a multigated acquisition (MUGA) scan was performed.
Time frame: Weeks 3, 9, and 15; EOT or early withdrawal; and 3- and 6-month survival follow-up after last chemotherapy course
Mean Intra-tumoral Expression of the Indicated Proteins at Baseline and Day 14
Expression (exp) of biomarker proteins (prot) were analyzed to determine if individual prot levels either in the Baseline or Day 14 breast tumor biopsy specimen correlated with breast pCR. A biomarker indicates a change in exp or state of a prot that correlates with the risk or disease progression, or with the susceptibility of the disease to a given treatment. Biomarkers are characteristic biological properties that can be detected and measured in parts of the body like blood or tissue. pCR=yes: participants (par.) had breast pCR. pCR=no: par. did not have breast pCR. Prot exp values are represented as normalized, scaled values; the unit of measurement is unit-less. Raw exp values were processed as follows: background subtraction of the raw exp value, then that value divided by beta-acting exp to normalize the exp value. A Standard Z score was calculated to scale the exp value.
Time frame: Tumor core biopsy taken at Baseline and Treatment Day 14
Cancer Stem Cells and the Correlation to Response/Non-response to Treatment
Stem cell data were of poor quality and thus could not be analyzed. Increases or decreases in cancer stem cells and how the changes correlated with response/non-response to treatment were to have been assessed.
Time frame: Tumor core biopsy taken at Baseline and Treatment Day 14
Transcriptional Profiling of Total RNA and the Correlation to Response/Non-response to Treatment
Transcriptional data were of poor quality and thus could not be analyzed. Gene pathways that correlate with response/non-response to treatment were to have been evaluated. The unit of measure is unit less; however, the processed values would be considered normalized relative expression level.
Time frame: Tumor core biopsy taken at Baseline and Treatment Day 14
| Milestone | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib |
|---|---|---|---|
| Started | 33 | 34 | 33 |
| Completed | 21 | 24 | 15 |
| Not completed | 12 | 10 | 18 |
| Withdrew: Lost to follow-up | 6 | 0 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 | 4 |
| Withdrew: Death | 0 | 2 | 3 |
| Withdrew: Adverse event | 1 | 2 | 3 |
| Withdrew: Did not complete study dosing | 1 | 0 | 0 |
| Withdrew: Worsening peripheral neuropathy | 1 | 0 | 0 |
| Withdrew: Disease progression | 0 | 4 | 1 |
| Withdrew: Disease recurrence | 0 | 1 | 0 |
| Withdrew: Sponsor request | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Completed 5 years | 0 | 0 | 1 |
A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ \[DCIS\] or lobular carcinoma in situ \[LCIS\] was allowed). A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus). Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes. 26 weeks of therapy comprised the 2-week run-in phase, 12 weeks of treatment with FEC, and 12 weeks of treatment with Paclitaxel.
| percentage of participants | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib |
|---|---|---|---|
| Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy | 54.0 | 45.0 | 74.0 |
cCR was defined as the percentage of participants achieving either a Complete Response (CR) or a Partial Response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.
| percentage of participants | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib |
|---|---|---|---|
| Percentage of Participants With Clinical Complete Response (cCR) at 26 Weeks or at End of Treatment (EOT) or Early Withdrawal | 61.0 | 68.0 | 61.0 |
Percentage is the Kaplan Meier estimate of DFS. DFS is time from randomization until disease recurrence (contralateral breast cancer; second primary cancer; progression during neo-adjuvant treatment; or death from any cause). Par. who experienced progression during treatment and were withdrawn were considered to have a DFS event at withdrawal.
| Percentage | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib |
|---|---|---|---|
| Percentage of Participants (Par.) With Disease-free Survival (DFS) at the End of 5 Years From Randomization | 90 (72 to 97) | 67 (47 to 80) | 66 (44 to 82) |
12-lead ECGs were performed, and participants were classified as having normal ECG, abnormal- not clinically significant (NCS) ECG, and abnormal-clinically significant (CS) ECG per investigator opinion and reported result.
| participants | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib |
|---|---|---|---|
| Baseline, Normal, n= 28, 32, 30 | 18 | 23 | 23 |
| Baseline, Abnormal-NCS, n= 28, 32, 30 | 10 | 8 | 7 |
| Baseline, Abnormal-CS, n= 28, 32, 30 | 0 | 1 | 0 |
| EOT/early withdrawal, Normal, n= 16, 21, 16 | 10 | 12 | 12 |
| EOT/early withdrawal, Abnormal-NCS, n= 16, 21, 16 | 6 | 8 | 4 |
| EOT/early withdrawal, Abnormal-CS, n= 16, 21, 16 | 0 | 1 | 0 |
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction and is used to determine cardiac function. LVEF was measured by performing echocardiogram (ECHO). If ECHO could not be performed or if the investigator believed that it was not conclusive to evaluate LVEF, then a multigated acquisition (MUGA) scan was performed.
| participants | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib |
|---|---|---|---|
| Week 3, n= 30, 31, 26 | 1 | 0 | 1 |
| Week 9, n= 30, 32, 27 | 1 | 0 | 1 |
| Week 15, n= 31, 34, 28 | 1 | 2 | 2 |
| Early withdrawal/EOT, n= 31, 34, 28 | 1 | 4 | 2 |
| 3-month survival follow-up, n= 31, 34, 28 | 2 | 4 | 3 |
| 6-month survival follow-up, n= 31, 34, 28 | 4 | 4 | 4 |
Expression (exp) of biomarker proteins (prot) were analyzed to determine if individual prot levels either in the Baseline or Day 14 breast tumor biopsy specimen correlated with breast pCR. A biomarker indicates a change in exp or state of a prot that correlates with the risk or disease progression, or with the susceptibility of the disease to a given treatment. Biomarkers are characteristic biological properties that can be detected and measured in parts of the body like blood or tissue. pCR=yes: participants (par.) had breast pCR. pCR=no: par. did not have breast pCR. Prot exp values are represented as normalized, scaled values; the unit of measurement is unit-less. Raw exp values were processed as follows: background subtraction of the raw exp value, then that value divided by beta-acting exp to normalize the exp value. A Standard Z score was calculated to scale the exp value.
| : normalized relative expression level | Trastuzumab | Lapatinib |
|---|---|---|
| Baseline, EGFR_Tyr1068; pCR=yes, n=0, 4 | NA ± NA | -0.70 ± 0.47 |
| Baseline, Baseline, EGFR_Tyr1068; pCR=no, n=0, 11 | NA ± NA | 0.05 ± 0.55 |
| Post Baseline, EGFR_Tyr1068; pCR=yes, n=9, 0 | 0.65 ± 1.02 | NA ± NA |
| Post Baseline, EGFR_Tyr1068; pCR=no, n=6, 0 | -0.26 ± 0.56 | NA ± NA |
| Day 14, pSTAT5; pCR=yes, n=11, 6 | NA ± NA | NA ± NA |
| Day 14, pSTAT5; pCR=no, n=9, 11 | NA ± NA | NA ± NA |
| Post Baseline, PI3K; pCR=yes, n=0, 5 | NA ± NA | 0.46 ± 0.73 |
| Post Baseline, PI3K; pCR=no, n=0, 10 | NA ± NA | -0.53 ± 0.67 |
| Post Baseline, LC3B; pCR=yes, n=0, 5 | NA ± NA | 0.68 ± 0.81 |
| Post Baseline, LC3B; pCR=no, n=0, 10 | NA ± NA | -0.43 ± 0.75 |
| Post Baseline, MMP9; pCR=yes, n=0, 5 | NA ± NA | 0.71 ± 0.34 |
| Post Baseline, MMP9; pCR=no, n=0, 5 | NA ± NA | -0.48 ± 0.48 |
| Post Baseline, GSK3_a_b_Tyr279_216; pCR=yes, n=8,0 | 0.26 ± 0.82 | NA ± NA |
| Post Baseline, GSK3_a_b_Tyr279_216; pCR=no, n=5,0 | -0.86 ± 0.67 | NA ± NA |
Stem cell data were of poor quality and thus could not be analyzed. Increases or decreases in cancer stem cells and how the changes correlated with response/non-response to treatment were to have been assessed.
No measurements were reported for this outcome.
Transcriptional data were of poor quality and thus could not be analyzed. Gene pathways that correlate with response/non-response to treatment were to have been evaluated. The unit of measure is unit less; however, the processed values would be considered normalized relative expression level.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab | — | 7/32 (21.9%) | 31/32 (96.9%) |
| Lapatinib | — | 7/34 (20.6%) | 34/34 (100%) |
| Trastuzumab+Lapatinib | — | 8/31 (25.8%) | 31/31 (100%) |
| Event | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib |
|---|---|---|---|
| Febrile nuetropeniaBlood and lymphatic system disorders | 3/32 | 0/34 | 2/31 |
| NeutropeniaBlood and lymphatic system disorders | 3/32 | 0/34 | 1/31 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/32 | 0/34 | 1/31 |
| PyrexiaGeneral disorders | 0/32 | 3/34 | 0/31 |
| DiarrhoeaGastrointestinal disorders | 0/32 | 2/34 | 2/31 |
| GastroenteritisInfections and infestations | 0/32 | 0/34 | 1/31 |
| Urinary tract infectionInfections and infestations | 0/32 | 0/34 | 1/31 |
| VomitingGastrointestinal disorders | 0/32 | 1/34 | 1/31 |
| NauseaGastrointestinal disorders | 0/32 | 0/34 | 1/31 |
| StomatitisGastrointestinal disorders | 0/32 | 0/34 | 1/31 |
| Event | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 17/32 | 29/34 | 31/31 |
| NauseaGastrointestinal disorders | 26/32 | 26/34 | 26/31 |
| RashSkin and subcutaneous tissue disorders | 14/32 | 28/34 | 26/31 |
| FatigueGeneral disorders | 22/32 | 24/34 | 24/31 |
| AlopeciaSkin and subcutaneous tissue disorders | 21/32 | 24/34 | 18/31 |
| Neuropathy peripheralNervous system disorders | 15/32 | 19/34 | 14/31 |
| NeutropeniaBlood and lymphatic system disorders | 13/32 | 12/34 | 15/31 |
| VomitingGastrointestinal disorders | 7/32 | 15/34 | 8/31 |
| AnemiaBlood and lymphatic system disorders | 10/32 | 12/34 | 12/31 |
| ConstipationGastrointestinal disorders | 12/32 | 8/34 | 6/31 |
| Age, Continuous(Years) | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib | Total |
|---|---|---|---|---|
| Mean | 51.1 ± 10.90 | 50.8 ± 8.76 | 49.2 ± 10.47 | 50.4 ± 10.01 |
| Sex: Female, Male(Participants) | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib | Total |
|---|---|---|---|---|
| Female | 33 | 34 | 33 | 100 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Trastuzumab | Lapatinib | Trastuzumab+Lapatinib | Total |
|---|---|---|---|---|
| African American/African heritage | 8 | 1 | 2 | 11 |
| American Indian or Alaska native | 0 | 0 | 1 | 1 |
| Asian - Central/South Asian heritage | 0 | 1 | 0 | 1 |
| Asian - East Asian heritage | 0 | 1 | 0 | 1 |
| Asian - South East Asian heritage | 0 | 2 | 1 | 3 |
| White - Arabic/North African heritage | 0 | 1 | 0 | 1 |
| White - White/Caucasian/European heritage | 25 | 27 | 29 | 81 |
| Mixed race | 0 | 1 | 0 | 1 |
The record gives a start of Aug 2007, a primary completion of Oct 2010 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab